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The death receptor Fas (Apo1/CD95) and Fas ligand (FasL) system is recognised as a major pathway for the induction of apoptosis
in vivo, and antiapoptosis via its blockade plays a critical role in carcinogenesis and progression in several malignancies. However, the
function of Fas–FasL system in urothelial cancer (UC) has not been elucidated. We therefore investigated the expression of Fas, FasL
and Decoy receptor 3 for FasL (DcR3) in UC specimens and cell lines, and examined the cytotoxic effect of an anti-Fas-activating
monoclonal antibody (mAb) in vitro. Immunohistochemical examinations of Fas-related molecules were performed on 123 UC and
30 normal urothelium surgical specimens. Normal urothelium showed Fas staining in the cell membrane and cytoplasm. In UC, less
frequent Fas expression was significantly associated with a higher pathological grade (Po0.0001), a more advanced stage (P¼0.023)
and poorer prognosis (P¼0.010). Fas and the absence thereof were suggested to be crucial factors with which to select patients
requiring more aggressive treatment. Moreover, low-dose anti-Fas-activating mAb sensitised resistant cells to adriamycin, and this
synergistic effect could be applied in the development of new treatment strategy for UC patients with multidrug-resistant tumours.
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Urothelial cancer (UC), which arises from the urothelium all the
way from the renal calices to urethra, is the second most frequent
urological malignancy after prostate cancer. Transitional cell
cancer (TCC), which is the most frequent type of UC, accounts
for more than 90% of all bladder cancers (Epstein et al, 1998).
Approximately 70% of tumours are superficial at initial diagnosis,
but of those about 60% recur and 10–20% of these progress (Ro
et al, 1992). Whereas survival is excellent in patients with
superficial disease, it falls substantially accordingly as the tumour
progresses. As representative prognostic markers, pathological
grade and tumour stage are very useful. However, as grade 2 UC
are still heterogeneous, there is a necessity to find new markers to
subclassify grade 2 tumours. In the treatment of advanced stage
bladder cancers, combination chemotherapy including platinum
has revealed promising results (Mead et al, 1998). However,
multidrug-resistant bladder cancer shows a poor prognosis.
Therefore, attempts to establish new treatment modalities are
being made. Bacille Calmette-Guerin (BCG) intravesical instillation
is an effective therapy for superficial UC, suggesting that utilisation
of the immune system may contribute to new treatment strategies.
Two major intracellular apoptotic signalling pathways are
known. In the type 1 cascade, death ligand–death receptor ligation
activates downstream death signals through caspase-8. The type 2
cascade is a mitochondrial pathway mainly regulated by the Bcl-2
family proteins. Fas (Apo1/CD95), TNFR-1, DR3, DR4 and DR5 are
well known as death receptors, and ligation by their specific
ligands delivers a direct and powerful signal that rapidly induces
apoptosis. Fas ligand (FasL) is produced by activated T cells and
natural killer (NK) cells, and it triggers the downstream apoptotic
signals through Fas. The Fas–FasL system is recognised as a major
pathway for the induction of apoptosis in cells and tissues (Nagata,
1997). Fas is widely expressed in normal and neoplastic cells,
but the expression of this protein does not necessarily predict
susceptibility to apoptosis. Recent studies suggested that resistance
to apoptosis with the Fas blockade might play an important role
in tumorigenesis and tumour progression in several malignancies,
including colorectal cancer (O’Connel et al, 1996) and malignant
glioma (Roth et al, 2001).
Several mechanisms for evading the Fas–FasL system have been
proposed. Principally, FasL-bearing tumour cells can induce Fas-
mediated apoptosis of antitumour lymphocytes bearing Fas, which
is known as the Fas–FasL tumour counterattack theory (O’Connel
et al, 1996). The validity of the Fas–FasL counterattack theory has
been studied in several malignancies, and FasL expression could be
a negative prognostic factor, such as in colorectal cancer (Mann
et al, 1999; Okada et al, 2000). Second, decoy receptor 3 (DcR3)
(TR6, M68), a decoy receptor for FasL, can play an important role
in various cancers (Pitti et al, 1998; Roth et al, 2001). Moreover,
recent study demonstrated that DcR3 expression might be a
clinical marker in colorectal cancer (Mild et al, 2002). The caspase-
8 homologue FLICE-inhibitory protein (FLIP) functions as a
caspase-8 dominant negative regulator, blocking signal transduc-
tion downstream of Fas (Irmler et al, 1997).
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and its decoy receptor DcR3 in 30 normal urothelium specimens,
123 UC surgical specimens and four UC cell lines of different
malignant potential. Moreover, we examined the association of
Fas expression with the cytotoxic effect of anti-Fas monoclonal
antibody (mAb) and adriamycin (ADM) in vitro. Among these
three Fas-related molecules, loss of Fas may have the greatest
impact on tumour progression leading to a poorer prognosis
among UC patients.
PATIENTS AND METHODS
Patients
A total of 123 patients with UC including bladder cancer (86),
ureteral cancer (20) and renal pelvic cancer (18), who underwent
surgical resection at our institution from 1987 to 2002, were
subjected to this study. Informed consent to perform the study was
obtained from all patients. Patients’ characteristics are presented
in Table 1. We selected only sequential cases of TCC, in which
tumour specimens were available, in this study. Histopathological
grading and staging were performed according to the 1999 WHO
and 1997 TNM classification, respectively.
Cells
Four established UC cell lines were obtained from the American
Type Culture Collection (ATCC). T24 (TCC), HT1376 (TCC) and
SCaBER (squamous cell carcinoma) were derived from high-grade
bladder cancer; the other, RT4 (TCC), was derived from low-grade
cancer. T24 is known to be multidrug resistant. DNA, RNA and
protein were extracted from cells when they reached subconfluence
according to protocols described previously (Tomita et al, 2003).
We used Jurkat, a lymphoma cell line, and SW480, a colon cancer
cell line, as controls. The former is well known as Fas expressing
cell, and the latter expresses various death receptors.
Reagents and antibodies
The four anti-Fas monoclonal antibodies (mAb) were used.
Apoptosis-inducing anti-Fas IgM (clone CH-11) and Fas-blocking
IgG (clone ZB4) from the Medical Bioscience Laboratory (MBL),
Nagoya, Japan were used for in vitro assays and flow cytometry.
Anti-Fas clone UB2 (MBL) and clone 13 (BD Trasduction
Laboratories, Tokyo, Japan) were used for immunohistochemistry.
There was no difference between these two antibodies in
immunoreactivity. Anti-FasL IgG clone Q-20 (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA), anti-DcR3 IgG (Upstate biotechno-
logy, Lake Placid, NY, USA), anti-caspase-8 IgG (MBL), anti-FLIP
IgG (ALEXIS, Tokyo, Japan) and anti-Bid Ig (BD, Tokyo, Japan)
were used for immunoblotting and immunohistochemistry.
Biotinylated secondary antibody, sheep anti-mouse and streptavidin-
horse radish peroxidase (HRP) were purchased from Amersham,
Aylesburg, UK, and HRP-conjugated goat anti-rabbit was from
Dako, Glostrup, Denmark. Adriamycin (Doxorubicin hydrochloride)
was purchased from Kyowa Hakko Kogyo, Tokyo, Japan.
Reverse transcription–polymerase chain reaction
(RT–PCR)
Reverse transcription–polymerase chain reaction was performed
according to a previously described protocol, with modifications
(Hara et al, 2002). Total RNA was extracted using ISOGEN
(Nippongene, Tokyo, Japan), according to the manufacturer’s
instructions. In total, 2mg of total RNA was used for the synthesis
of cDNA with a first-strand cDNA synthesis kit (Roche Diganostics,
Tokyo, Japan). The first strand cDNA (1ml) was then used for
PCR with primers designed to amplify the target sequences given
in Table 2. Amplification was carried out with an initial
denaturation at 941C for 5min, followed by 35 cycles of 1min
denaturation at 941C, 1min annealing at the temperature listed
in Table 2, and 1min extension at 721C, then a final extension for
5min at 721C.
Real-time quantitive PCR
High molecular weight DNA was isolated from tumour tissues and
cell lines using the phenol–chloroform extraction method. Real-
time PCR detection was performed in triplicate on the ABI Prism
7700 using a TaqMan instrument (Applied Biosystems, Tokyo,
Table 1 Patient characteristics
Mean age (range) years 66.9 (41–89)
Male/female 92/32
Renal pelvic cancer 18
Ureteral cancer 20
Bladder cancer 86
(TUR-BT/total cystectomy) (37/49)
Histopathological grading
G1 11
G2 69
G3 43
Pathological staging
Ta 17
T1 52
T2 18
T3 28
T4 8
Mean follow up (range), months 64.3 (0–192)
TUR-BT: transurethral resection of bladder tumour.
Table 2 Primers sequences for RT–PCR and real-time PCR
Specificity forward (50-30) Reverse (50-30) Product size (bps) Annealing T. (1C)
RT–PCR
Fas atgctgggcatctggaccct gccatgtccttcatcacacaa 335 58
FasL aactcaaggtccatgcctctg ggtgagttgaggagctacagaca 553 58
DcR3 gccactacacgcagttctggaacta gaggaagagcctggcacattgaggg 336 60
DR4 attgtacgccctggagtgac aaggacacggcagagcctgtgccat 741 60
DR5 ctgaaaggcatctgctcaggtg cagagtctgcattaccttctag 582 58
DcR1 gccggaagtgtagcaggtg ggggcaggggcaggcgtttct 546 58
DcR2 cttttccggcggcgttcatgtccttc gtttcttccaggctgcttccctttgtag 463 58
b-ACT aatgcttctaggcggact actcccagggagaccaaa 533 58
Real-time PCR
DcR3 cttcttcgcgcacgctc atcacgccggcaccag
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nucleotide sequences for primers are described previously (Pitti
et al, 1998). To enable the standardisation of DNA quantity,
TaqMan b-actin real-time PCR was performed for each sample,
and the results were used to adjust the final results of real-time
PCR for DcR3. Each normalised target value was divided by
the calibrator-normalised target value to calculate the relative
expression level.
Immunoblotting and immunohistochemistry
Immunoblot analysis was performed as described previously
(Tomita et al, 2003). The cell lysates were subjected to electro-
phores on 12 or 15% SDS–polyacrylamide gels, then electroblotted
to Hybond-ECL super membranes (Amersham). The blots were
blocked with 5% nonfat milk, and then incubated with the
antibodies described above. After three washes with Tris-buffered
saline (pH 7.6), containing 0.1% Tween-20, the blotted membranes
were incubated with biotinylated secondary antibodies and
subsequently with peroxidase-conjugated streptavidin (Amersham).
Visualisation of stained blots was performed with the ECL
Western Blotting Detection system (Amersham) according to the
manufacturer’s instructions. Immunohistochemical staining was
performed using the avidin–biotin peroxidase complex method
with 5mm cryostat sections from frozen tissue as described earlier
(Itoi et al, 2004). We classified the immunoreactivity as positive or
negative. We observed two different patterns of staining: a
homogeneous strong staining or heterogeneous staining of more
than 60% of all cells, which we defined as positive; and less than
60% positive staining in tumour cells, which was defined as a
negative pattern. There were no intermediate pattern samples and
most of negative tumours showed less than 25% positive cells.
Infiltrating lymphocytes showing Fas expression were used as an
internal positive control.
In vitro cell toxic assay
We examined the possible modulation of Fas and FasL expression
following ADM treatment in RT4 and T24. The reasons we selected
these cell lines are that both of them are derived from transitional
cells and similar in Fas, FasL and DcR3 status, while the former is
susceptible to ADM and the latter is highly resistant. The MTT
conversion assay (Chemicon International Inc., Temecula, CA,
USA) was used to estimate cell viability (Tomita et al, 2003). After
trypsinisation and washing, cells were resuspended in the medium,
and added to a 96-well flat-bottom plate (167008 Nunk, Roskilde,
Denmark), at 5 10
3 cells per well in 100ml of the medium. The
cells were cultivated at 371C with 5% CO2 for 3h and then
subjected to treatment with anti-Fas antibodies in combination
with ADM or without it. At 4h prior to the end of the assay, 10ml
of MTT solution was added to each well, containing both attached
viable cells and detached apoptotic cells, and the incubation was
carried out for 4h. All functional experiments were accompanied
with a control – Jurkat cells. Absorbance was evaluated at 570nm
with a Multiplate Reader (Bio Rad, Hercules, CA, USA). Each dose
was applied in six wells and the mean and standard deviation were
calculated. Each experiment was repeated at least three times.
Flow-cytometric analysis
For flow-cytometric analysis, cells were stained by the indirect
immunofluorescence method as described (Bilim et al, 2003).
Briefly, tumour-cell suspensions were prepared by treatment with
0.125% trypsin and 0.02% EDTA. Tumour cells (1 10
6) were
reacted for 30min at 41C with anti-Fas mAb in PBS supplemented
with 2% FCS and 0.02% sodium azide. After two washes by
centrifugation, cells were incubated with FITC-conjugated rabbit
anti-mouse Ig (DAKO) for 30min at 41C. Subsequently, the cells
were washed three times and suspended at a concentration of
1 10
6 cellsml
 1 and analysed by flow cytometry (FACScanTM,
Becton Dickinson, Mountain View, CA, USA). Jurkat cells, known
to express Fas on the cell membrane, were used as a positive
control. As negative control, first antibody was substituted with
mouse Ig (DAKO).
Statistical analysis
Statistical analysis was performed using Stat View 5.0 for
Macintosh. Associations of Fas, FasL and DcR3 expression with
clinicopathologic parameters were tested with chi-square test and
Fisher’s exact test of variance. The survival analysis was performed
using Kaplan–Meier method as the end point for disease-specific
survival, and the differences between groups were tested using log-
rank test.
RESULTS
Expression of Fas, FasL, DcR3 and other death receptors in
human UC cell lines
The expression of Fas, FasL and DcR3 was assessed by RT–PCR
(Figure 1). The expression of other death receptors, DR4 and DR5,
and decoy receptors, DcR1 and DcR2, was assessed by RT–PCR.
All cell lines expressed these molecules at different levels (Figure 1).
All four cell lines expressed equal levels of Fas, FasL and DcR3
except HT1376 cells which showed much less FasL. Expression of
cell surface Fas was confirmed at the protein level by FACS
analysis, and the levels were the same among the examined cell
lines (Figure 2A). FasL expression was confirmed at the protein
level by immunoblotting, and the expression levels were variable
(Figure 2B).
335 bp
553 bp
336 bp
741 bp
582 bp
546 bp
463 bp
533 bp
Fas
FasL
DcR3
DR4
DR5
DcR1
DcR2
-Actin
100 bp
ladder
P.C. N.C. RT4 T24 HT1376 SCaBER
Figure 1 Reverse transcription–PCR of Fas-related molecules, Fas, FasL
and DcR3 and other death receptors in human bladder cancer cell lines.
The primer sequences and annealing temperatures are listed in Table 2.
We selected Jurkat (Fas, DcR2) and SW480 (FasL, DcR3, DR4, DR5,
DcR1) as positive controls (P.C.). Negative control (N.C.) without cDNA
template was also applied.
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We examined the possible modulation of Fas and FasL expression
following ADM treatment in RT4 and T24. We did not find
any upregulation of Fas expression after the exposure to ADM
(data not shown). On the other hand, the exposure resulted in
a downregulation of FasL expression in T24 but not RT4. In
addition, proapoptotic member of Bcl-2 family proteins, Bid was
processed to its active form tBid in a dose-dependent manner
in T24, although cell death was not induced. ADM triggered
procaspase-8 cleavage into active subunits in RT4 (Figure 2C).
ZB4 Fas-blocking antibody did not affect the viability of either
naı ¨ve or ADM-treated cells (data not shown). Treatment with
CH-11 Fas-activating antibody did not have any effect on the
viability of T24 cells except at an extremely high concentration
(1000mgml
 1) at which viability decreased by less 20% (Figure 3).
Intensity FL-1
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r
Negative control
RT4
T24
FasL
FLIP
-Actin
-Actin
Positive
cotntrol
RT4 T24 HT1376 SCaBER Jurkat Normal
urothelium
Caspase-8
Bid
tBid
FasL
0 0.1 1 10 0 0.1 1 10
T24 RT4
54–55 kDa
24 kDa
15 kDa
37 kDa
46 kDa
ADM
g ml–1
24 h
37 kDa
58 kDa
46 kDa
A
B
C
Figure 2 (A) FACScan analysis for cell surface Fas in T24 and RT4 cell lines. (B) Immunoblotting for FasL and FLIP in UC cell lines and normal urothelium
compared with two control cell lines; SW480 to FasL and HEK 293T cells transfected with human FLIP. A single band of 37kDa for FasL and 58kDa for FLIP
were detected. b-Actin was applied as a control for loading. (C) Immunoblotting for FasL, caspase-8 and Bid in T24 and RT4 cell lines following ADM
treatment.
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effect in both T24 and RT4. This synergistic effect started from
1ngml
 1 of CH-11 and 1mgml
 1 of ADM (Figure 3).
Fas expression in normal urothelia and UC specimens
We demonstrated Fas expression in the normal urothelium and
UC by immunohistochemistry. Fas was detectable in both the
cytoplasm and plasma membrane of normal ulothelial cells and
UC cells but not in the nuclei (Figure 4A and B). The normal
urothelium showed a homogeneous expression in 27 out of 30
cases (90.0%), and the UC showed immunoreactivity for Fas in 72
of 123 cases (58.5%) (Table 3A). Fas expression inversely
correlated with higher histopathological grade (G1: eight out of
11 (72.7%), G2: 50 out of 69 (72.5%), G3: 14 out of 43 (32.6%)).
G1-2 tumours expressed Fas more frequently than G3 tumours
(Po0.0001). A less frequent Fas expression was associated with a
more advanced pathological stage (Ta: 13 out of 16 (81.3%), T1: 32
out of 52 (61.5%), T2: 10 out of 18(55.6%), T3: 12 out of 28
(42.9%), T4: three out of eight (37.5%)) (Table 3A). A significantly
high proportion of Ta-1 tumours than T2-4 tumours expressed
Fas (P¼0.023). Fas-positive cases showed a significantly better
prognosis (P¼0.010, Figure 5A). When patients’ survival was
analysed in grade 2 tumours only, the same result was obtained
(P¼0.007, Figure 5B).
FasL and DcR3 expression in normal urothelium and UC
specimens
Decoy receptor 3 for FasL gene amplification was examined in cell
lines and 20 bladder cancer specimens by real-time quantitive
PCR. The T24 cell line and five of 20 UC had a copy number of two
or more (Figure 6). We analysed the characteristics of five cases
of DcR3 gene amplification. DNA amplification was not directly
associated with the immunohistochemical pattern of DcR3 staining
and clinical parameters in these patients. Fas ligand and DcR3 were
also expressed in both the cytoplasm and plasma membrane. The
expression of FasL was detected in UC (37.6%) and normal
urothelium (23.3%, Table 3B). Fas ligand expression was present
more frequently in G1-2 than in G3 tumours (Po0.0001), and
tended to be more frequent in Ta-1 than T2-4 (P¼0.061). DcR3
expression was detected in UC (90.0%) and normal urothelium
(80.7%). The expression of DcR3 correlated with neither histo-
pathological grade nor pathological stage (Table 3B). The
expression of these two molecules did not have an association
with disease-specific survival.
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Figure 3 MTT cell viability assay of T24 cells treated with either ADM
or CH-11 Fas-activating antibody, or a combination of both. Adriamycin
or/and CH-11 were added to the culture medium at the indicated
concentrations and MTT assay was performed 24h later.
Figure 4 Immunohistochemical staining of Fas. (A) Normal urothelium
shows staining of membranes and cytoplasm. (B) Grade 2 bladder cancer
shows a homogeneous staining pattern. (C) Grade 3 bladder cancer is
negative. Scale bar is 50mm long.
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sDISCUSSION
Previously, we have demonstrated the inverse correlation of Bcl-2
protein level with sensitivity to ADM treatment in TCC cell lines
(Bilim et al, 1997). Besides, ADM treatment alone did not have any
direct influence on the expression level of antiapoptotic Bcl-2
or Bcl-xL. Here, we have got evidence that Bid, which is a
proapoptotic member of Bcl-2 family proteins, was processed to its
cleaved active form in a dose-dependent manner in TCC cells
including T24, a multidrug-resistant cell line (Figure 2C). More-
over, ADM triggered procaspase-8 cleavage into active subunits
(Figure 2C) and drastic increase of IETD-caspase-8-specific
activity in susceptible cells (data not shown). These events
suggested that ADM treatment could activate Fas and subsequent
apoptotic signal transduction in TCC. To confirm or disprove this
working hypothesis and get direct evidences, we proceeded to
functional in vitro assays.
The expression of Fas was observed in each of four UC cell lines
of different malignant potential and morphological type. Expres-
sion levels were similar among them. Despite the expression of Fas,
treatment with CH-11 Fas-activating antibody alone did not have
any cytotoxic effect in either T24 or RT4. However, we obtained
a synergistic effect with ADM and CH-11 both in T24 and RT4.
Furthermore, this synergic effect was demonstrated with low-dose
CH-11. On this occasion, we did not find any upregulation of Fas
expression after the exposure to ADM, and ZB4 Fas-blocking
antibody did not affect the viability of either naı ¨ve or ADM-treated
cells. These findings suggested that the apotosis induction by
CH-11 is not dependent on the quantity of Fas receptor, and the
main regulation mechanism might exist somewhere downstream
in the signal cascade.
Published studies have shown that apoptosis through the
activation of several caspases by chemotherapy using ADM did
not depend on Fas–FasL interaction in other cancers (Gamen et al,
1997; Landowski et al, 1999), among them ADM downregulated
FLIP, an antiapoptotic downstream molecule of Fas, in prostate
cancer cell lines, which lead to sensitise cancer cells to death
receptor-mediated apoptosis (Kelly et al, 2002). However, we did
not find any correlation of FLIP expression with ADM suscepti-
bility in UC cell lines (data not shown). We had reported that ADM
triggered a type 2 apoptosis cascade, mitochondrial pathway, in
UC (Bilim et al, 1997). On the other hand, several investigators
showed that ADM treatment induced Fas or FasL upregulation
and led to apoptosis via Fas–FasL interaction (Friesen et al, 1996;
Mizutani et al, 1997; Villunger et al, 1997). The present study was
not consistent with these previous reports; ADM treatment
sensitised TCC cells to CH-11 without change in Fas expression
level. This synergistic effect can be explained by the amplification
of the downstream apoptosis cascade through the convergence of
type 1 and 2 cascades activated by Fas and ADM, respectively. The
convergent point might be in mitochondria, and the regulator of
signal downstream could be proapoptotic Bcl-2 family proteins,
such as Bid and Bax. There is increasing evidences from other
tumour cites showing the role of Bid or Bax as regulator of
apoptosis (Fukazawa et al, 2003; Schniewind et al, 2004). Direct
induction of Fas-mediated apoptosis may be a promising strategy
for an anticancer therapy particularly in combination with
chemotherapy. However, severe systemic and potentially lethal
toxicity by the attempts to administrate Fas agonists has been the
major obstacle for its use of anticancer therapy. To avoid these
harmful adverse events, intraperitoneal injection of Fas was tried
and it revealed antitumour effect without systemic toxicity
(Rensing-Ehl et al, 1995). In addition, presence of glycosamino-
glycans covering the normal urothelium might be a natural barrier
to prevent adverse effects of Fas agonist to the Fas presenting
normal urothelial cells (Parsons et al, 1990; Shimizu et al, 2001).
Thus, less toxic and more efficient antitumour effects may be
expected by intravesical administration of the reagents, whereas
further examination is warranted in addition to our data presented
here.
We investigated the expression of Fas, FasL and DcR3 in 123
UC surgical specimens as well as 30 normal urothelial specimens
by immunohistochemistry. It was found that loss of Fas was
associated with clinical parameters. The majority of normal
urothelial specimens expressed Fas, whereas in UC, Fas was
downregulated. Furthermore, Fas immunoreactivity inversely
correlated with higher pathological grade (Po0.0001), higher
tumour stage (P¼0.023) and shorter cause-specific survival
Table 3A Correlation of Fas expression with grade or stage
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Figure 5 Desease-specific survival of UC patients according to Fas
expression by the Kaplan–Meier estimation. (A) In all cases. (B) In grade 2
tumour cases only; Fas-negative status of tumours was associated with
significantly poorer prognosis.
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s(P¼0.010). The disappearance of Fas may be a result of cancer
progression, manifesting most apparently with dedifferentiation
of cancer cells. In the present study, different tumours of the
same grade, the most common criteria of cell malignancy and
differentiation status, revealed various Fas status, which correlated
with the prognosis. Therefore, we assumed that Fas on UC cells
might have its function as a death receptor, and decreased Fas
may contribute to acquisition of higher malignant potential.
These results conflicted with two previous reports in which Fas
expression had no correlation with clinicopathological variables
(Lee et al, 1999; Giannopoulou et al, 2002). Recently, Maas et al
(2004) reported that Fas downregulation was related to higher
tumour stage the same as ours. On the contrary, they did not
observe correlation with tumour grade and survival. In these
studies, different antibodies were used for IHC (rabbit polyclonal
C-20 or N-18, Santa Cruz); moreover, the results were based on a
small number of patients. Fas downregulation is recognised as one
of the mechanisms for evading the Fas–FasL system in other types
of tumours, and a similar loss of Fas was shown to be a negative
prognostic factor in acute lymphoblast leukaemia (Suminoe et al,
2004), lung cancer (Koomagi and Volm, 1999) and pancreatic
cancer (Bernstorff et al, 2002). In the present study, grade 2
UC were presumably heterogeneous in terms of biological charac-
teristics. Namely, some grade 2 UC progressed dramatically
(n¼13) while others showed no recurrence (n¼56). Therefore,
new factors, which can be used to subclassify grade 2 tumours, are
needed for determining treatment strategy in this category. The
current study suggests that grade 2 UC could be subclassified
according to Fas expression. As was observed here, Fas-negative
patients had a poor prognosis, which was also true of grade 2
tumours, indicating the possibility of applying Fas expression as a
useful prognostic parameter in grade 2 UC.
Another aspect of the Fas–FasL system is FasL expression in
cancer cells. Recently, Chopin et al (2003) reported FasL
expression in a series of 44 UC specimens and showed that UC
acquired a functional FasL with progression to a higher grade and
stage. They applied A11 and H11 (Alexis, Lausen, CH) clones of
FasL antibodies for immunohistochemical staining in this rather
small patient cohort. Our results also demonstrated that FasL was
expressed more frequently in UC than normal urothelium.
However, FasL expression showed an inverse correlation with
tumour grade and stage. This discrepancy cannot be fully
explained, but it may be due to the use of different clones of
antibodies and the large gap in patient number. There is problem
in the reliability of antibodies for FasL, and several papers have
tested their specificity; many clones including A11 and H11were
listed as unreliable, on the other hand, because clone Q-20 we used
had not been examined, we cannot give any other evidences
besides our own results for the reliability of the antibody, but other
clones of Santa Cruz were considered not applicable for IHC
(Strater et al, 2001). As for the patients’ survival, FasL expression
showed no correlation with it. Our results on FasL do not support
the Fas–FasL tumour counterattack theory in UC. In addition,
DcR3, a decoy receptor for FasL, drew attention as a new molecule
working to evade activation of the Fas–FasL system (Pitti et al,
1998). In several other malignancies, DcR3 gene amplification and
expression were reported (Roth et al, 2001; Mild et al, 2002). This
study is the first report on the gene and protein status of DcR3 in
normal urothelium and UC. Whereas amplification and expression
were seen in some cases of UC, DcR3 showed no correlation with
tumour grade, tumour stage or patients’ survival.
In conclusion, among Fas-related molecules in UC, Fas and
the absence thereof may have the greatest impact on tumour
progression through evading apoptosis leading to a poorer
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Figure 6 Quantitative PCR of DcR3. Relative gene copy number as a measure of DcR3 gene amplification in human bladder cancer cell lines and
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Table 3B Correlation of FasL and DcR3 expression with grade or stage
Prognostic impact of FAS/CD95/APO-1 in urothelial cancers
K Yamana et al
550
British Journal of Cancer (2005) 93(5), 544–551 & 2005 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sprognosis. Thus, the loss of Fas was suggested to be a crucial factor
for selecting patients requiring more aggressive treatment. This
is especially important for G2 tumours. Furthermore, low-dose
anti-Fas-activating mAb sensitised resistant cells to ADM, and this
synergistic effect was independent from expression level of Fas
receptor, although the presence of Fas was essential. This effect
could be applied in the development of new treatment strategy for
UC patients with multidrug-resistant tumours.
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